Gene therapy specialist AskBio Inc, a wholly owned and independently operated subsidiary of German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY), announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB-1009.
The product is an investigational adeno-associated virus (AAV) gene therapy being developed for the treatment of late-onset Pompe disease.
With this announcement, the AB-1009 programme progresses to Phase 1/2 and AskBio will commence a clinical trial in the United States to explore the safety of AB-1009. The company anticipates recruiting the first patient in early 2026.
In September 2024, AskBio formed a strategic collaboration with Belief BioMed (BBM) to explore the potential for new gene therapies. BBM granted AskBio a sublicence to use the proprietary AAV capsid in the AB-1009 programme and provided AAV vector production services.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval